COMBINED MODALITY TREATMENT USING RADIATION AND OR CHEMOTHERAPY IN AN ATHYMIC (NUDE) MOUSE-HUMAN MEDULLOBLASTOMA AND GLIOBLASTOMA XENOGRAFT MODEL

被引：0
|
作者：
SLAGEL, DE
FEOLA, J
HOUCHENS, DP
OVEJERA, AA
机构：
[1] UNIV KENTUCKY,COLL MED,DEPT SURG & RADIAT THERAPY,LEXINGTON,KY 40506
[2] BATTELLE MEM INST,COLUMBUS LABS,COLUMBUS,OH 43201
来源：
EXPERIMENTAL CELL BIOLOGY | 1982年 / 50卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：347 / 347
页数：1
相关论文
共 36 条
  • [21] Combined-modality treatment of esophageal and head and neck cancer using paclitaxel/carboplatin-based chemotherapy concurrently with radiation therapy
    Hainsworth, JD
    Burris, HA
    Meluch, AA
    Greco, FA
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 62 - 62
  • [22] RAPID DETECTION OF HUMAN-BREAST CARCINOMA XENOGRAPHS USING TECHNETIUM-99M 323/A3 FAB' IN AN ATHYMIC NUDE-MOUSE MODEL
    PAK, KY
    NEDELMAN, MA
    FOGLER, WE
    MCGUIRE, WL
    DADDONA, PE
    BREAST CANCER RESEARCH AND TREATMENT, 1988, 12 (01) : 145 - 145
  • [23] K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis:: An in vivo study using the severe combined Immunodeficient mouse-human skin model
    Raychaudhuri, SR
    Sanyal, M
    Weltman, H
    Kundu-Raychaudhuri, S
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : 812 - 819
  • [24] Enhanced antitumor activity of a combination treatment with a mouse human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model
    Yamamoto, T
    Arakawa, F
    Nakamura, K
    Senba, T
    Tomita, Y
    Ikeda, S
    Kuroki, M
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1999, 48 (04) : 165 - 171
  • [25] Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model
    Takafumi Yamamoto
    Fumiko Arakawa
    Ken Nakamura
    Tarumi Senba
    Yoshihiro Tomita
    Seiyo Ikeda
    Masahide Kuroki
    Cancer Immunology, Immunotherapy, 1999, 48 : 165 - 171
  • [26] Successful treatment of human high-risk neuroblastoma using 177Lu-octreotide combined with Lorlatinib in a mouse model
    Forssell-Aronsson, E.
    Romiani, A.
    Pettersson, D.
    Simonsson, K.
    Bakr, H.
    Lind, D.
    Kovacs, A.
    Palmer, R.
    Hallberg, B.
    Helou, K.
    Spetz, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S340 - S340
  • [27] Cetuximab-F(ab′)2-SPECT and FDG-PET for prediction and response monitoring of combined modality treatment of human head and neck carcinomas in a mouse model
    van Dijk, L. K.
    Bussink, J.
    Franssen, G. M.
    Boerman, O. C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S273 - S273
  • [28] Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma
    Xu, Qingxing
    Leong, Jiayu
    Chua, Qi Yi
    Chi, Yu Tse
    Chow, Pierce Kah-Hoe
    Pack, Daniel W.
    Wang, Chi-Hwa
    BIOMATERIALS, 2013, 34 (21) : 5149 - 5162
  • [29] Dynamic contrast–enhanced ultrasonographic (DCE-US) assessment of the early response after combined gemcitabine and HIFU with low-power treatment for the mouse xenograft model of human pancreatic cancer
    Jung Hoon Kim
    Haeri Kim
    Young Jae Kim
    Jae Young Lee
    Joon Koo Han
    Byung-Ihn Choi
    European Radiology, 2014, 24 : 2059 - 2068
  • [30] Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy
    McPherson, Christopher M.
    Gerena-Lewis, Margie
    Breneman, John C.
    Warnick, Ronald E.
    JOURNAL OF NEURO-ONCOLOGY, 2012, 108 (03) : 521 - 525
1234